WILMINGTON, Del., Jan. 12, 2026 (GLOBE NEWSWIRE) — AOP Health US, LLC announced today that Rapiblyk™ (landiolol) is now more widely available across the United States through Cardinal, Cencora Specialty Distribution, McKesson Corporation, and M&D Specialty Distribution. Hospitals and health systems nationwide can now access Rapiblyk™ through their preferred purchasing channels, enhancing flexibility while expanding the availability of this critical care therapy.
“This represents an important milestone in ensuring that Rapiblyk™ availability is secured nationwide, supporting clinicians and healthcare providers in critical care environments,” said John Kimmet, General Manager of AOP Health US. “We’re reinforcing our commitment to making Rapiblyk™ accessible where it’s needed most.”
AOP Health US previously announced the U.S. commercial availability of Rapiblyk™ (landiolol), an ultra-short-acting, selective beta-1 adrenergic receptor blocker approved by the U.S. Food and Drug Administration (FDA) for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (SVT) or irregular rapid heart rate, including atrial fibrillation and atrial flutter, in critical care settings.
Ordering Information:
Healthcare professionals can order Rapiblyk™ via the following wholesalers:
Cardinal
Rapiblyk™ Item Number: 6055347
Phone Number: +1 800 926 3161
Website: https://orderexpress.cardinalhealth.com
Cencora Speciality Distribution
Rapiblyk™ Item Number: 10301954
Phone Number: +1 800 746 6273
Email: [email protected]
McKesson
Rapiblyk™ Item Number: 3051620
Phone Number: +1 800 793 9875
Website: https://mscs.mckesson.com
Morris & Dickson
Rapiblyk™ Item Number: 056722
Phone Number: +1 800 388 3833
Email: [email protected]
Prescribing information can be found at www.rapiblyk.com
About Rapiblyk™
Rapiblyk™ (landiolol) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (SVT) or irregular rapid heart rate, including atrial fibrillation and atrial flutter, especially in perioperative, postoperative, or critical-care settings. Rapiblyk™ provides rapid onset and offset of action, allowing clinicians to achieve precise, controlled rate management with a favorable hemodynamic profile.
The product is supplied as an intravenous infusion designed for use in a monitored hospital setting.
INDICATION
Rapiblyk™ is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Rapiblyk™ is contraindicated in patients with:
- Severe sinus bradycardia, sick sinus syndrome, or >1st-degree AV block
- Decompensated heart failure
- Cardiogenic shock
- Pulmonary hypertension
- Known hypersensitivity to landiolol or formulation components
WARNINGS AND PRECAUTIONS
Includes risk of hypotension, bradycardia, cardiac failure, bronchospasm, masking of hypoglycemia symptoms, infusion site reactions, worsening of Prinzmetal’s angina, complications in pheochromocytoma, peripheral vascular disease, abrupt withdrawal effects, hyperkalemia, metabolic acidosis, and unresponsiveness to epinephrine in hypersensitivity reactions.
ADVERSE REACTIONS
Most important and common adverse reaction is hypotension which in clinical trials occurred in 9.9% of patients receiving RAPIBLYK vs. 1% in those receiving placebo. Please consult the full Prescribing Information for Rapiblyk™: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217202s000lbl.pdf
About AOP Health
AOP Health is a global enterprise with roots in Austria and a mission to address unmet medical needs through innovative, science-driven therapies in cardiovascular and rare disease. Since 1996, the AOP Health Group has been recognized as a pioneer in developing integrated therapy solutions that combine deep scientific expertise with a strong commitment to patient and physician needs.
Building on this foundation, AOP Health US, LLC was established in 2025 to expand the company’s impact in the United States. The team is focused on introducing its 2024 US FDA approved product for use in the critical care setting, while building the infrastructure to support healthcare professionals and the patients they serve.
Contact
Nina Roth, MAS
[email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/99487cf4-0396-4751-8656-1171d750959b